A joint venture between industry veterans launched a new player in the future of cell and gene therapies. ScaleReady delivers rapid expansion of potentially life-saving T-cells to treat cancer and other conditions by reducing the complexity and cost of production.

ScaleReady logo

01 —


ScaleReady’s mission is to accelerate the groundbreaking advances in cell and gene therapy by satisfying the longstanding need for a truly scalable, cost-effective and practical manufacturing platform.

ScaleReady needed key messages to differentiate its brand and mission to create consistency across earned, owned and shared platforms in a competitive and innovative industry.

02 —


  • Build a strategic communication launch plan with specific focus on earned, owned and shared channels
  • Established consistent key messages understandable for the med-tech community, media and general public
  • Activate the plan to drive differentiated brand awareness to generate leads
  • Balance the technology and human benefit elements of the story to create appeal beyond the bio-technology industry

03 —


  • ScaleReady experienced successful media and social media coverage despite interruption of the launch day news cycle by a violent siege at the U.S. Capitol.
  • Launch press release received more than 19 million impressions and 43 news stories
  • Proactive media pitching resulted in six feature stories, including influential industry trade publications and local market business media
  • The newly launch LinkedIn channel was supported by social selling, resulting in 3,300% follower growth, 11% engagement and 7% click through rates — all well above average social media performance metrics

By using our website, you agree to our privacy policy and our use of cookies, which helps us improve your browsing experience. More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.